As of 2026-10-12, the Relative Valuation of Madrigal Pharmaceuticals Inc (MDGL) is (361.61) USD. This relative valuation is based on P/E multiples. With the latest stock price at 471.75 USD, the upside of Madrigal Pharmaceuticals Inc based on Relative Valuation is -176.7%.
The range of the Relative Valuation is (297.46) - (393.05) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 21.1x - 27.9x | 25.6x |
| Forward P/E multiples | 19.2x - 28.3x | 25.7x |
| Fair Price | (297.46) - (393.05) | (361.61) |
| Upside | -163.1% - -183.3% | -176.7% |
| Date | P/E |
| 2026-10-09 | -33.46 |
| 2026-10-08 | -33.83 |
| 2026-10-07 | -34.60 |
| 2026-10-06 | -35.21 |
| 2026-10-05 | -35.01 |
| 2026-10-02 | -35.42 |
| 2026-10-01 | -35.45 |
| 2026-09-30 | -35.75 |
| 2026-09-29 | -36.14 |
| 2026-09-28 | -36.68 |
| 2026-09-25 | -36.64 |
| 2026-09-24 | -36.40 |
| 2026-09-23 | -36.39 |
| 2026-09-22 | -36.80 |
| 2026-09-21 | -37.02 |
| 2026-09-18 | -37.70 |
| 2026-09-17 | -37.91 |
| 2026-09-16 | -37.53 |
| 2026-09-15 | -37.12 |
| 2026-09-14 | -38.31 |
| 2026-09-11 | -37.91 |
| 2026-09-10 | -37.82 |
| 2026-09-09 | -38.78 |
| 2026-09-08 | -37.89 |
| 2026-09-04 | -38.38 |
| 2026-09-03 | -38.49 |
| 2026-09-02 | -38.80 |
| 2026-09-01 | -38.21 |
| 2026-08-31 | -38.31 |
| 2026-08-28 | -37.86 |
| 2026-08-27 | -38.57 |
| 2026-08-26 | -38.22 |
| 2026-08-25 | -36.33 |
| 2026-08-24 | -36.32 |
| 2026-08-21 | -36.65 |
| 2026-08-20 | -36.82 |
| 2026-08-19 | -38.32 |
| 2026-08-18 | -37.20 |
| 2026-08-17 | -37.23 |
| 2026-08-14 | -36.00 |
| 2026-08-13 | -35.99 |
| 2026-08-12 | -38.03 |
| 2026-08-11 | -37.97 |
| 2026-08-10 | -36.55 |
| 2026-08-07 | -36.18 |
| 2026-08-06 | -36.20 |
| 2026-08-05 | -36.47 |
| 2026-08-04 | -36.00 |
| 2026-08-03 | -34.19 |
| 2026-07-31 | -33.15 |